Healthcare Industry News: S.A.
News Release - January 24, 2013
Baxter Announces Agreement to Acquire Investigational Hemophilia Compound OBI-1 and Related Assets
DEERFIELD, Ill.--(Healthcare Sales & Marketing Network)--Baxter International Inc. (BAX) announced today that it haS.A.reed to acquire the investigational hemophilia compound OBI-1 and related assets from Inspiration BioPharmaceuticals, Inc. as well as certain other OBI-1 related assets, including manufacturing operations, from Ipsen Pharma S.A.S. in conjunction with Inspiration’s ongoing bankruptcy proceedings. The transaction is subject to bankruptcy court and regulatory approvals.OBI-1 iS.A.recombinant porcine factor VIII (rpFVIII) being investigated for the treatment of bleeding in people with acquired hemophilia A and congenital hemophilia A patients with inhibitors. Acquired hemophilia A iS.A.rare, potentially life-threatening bleeding disorder, which, unlike congenital hemophilia, typically affects older adultS.A.d occurs equally in both maleS.A.d females.
''OBI-1 has the potential to address existing unmet needs of hemophilia patientS.A.d iS.A.strong strategic fit with Baxter’s current hemophilia portfolio,'' said Bruce Ewenstein, M.D., Ph.D., vice president of clinical affairs in Baxter’s BioScience business.
Under the terms of the agreement, Baxter will make an upfront payment of $50 million for the OBI-1 assets, including the manufacturing operations. In the future, Baxter may make payments of up to $20 million in total based on regulatory approval of the acquired hemophilia A indication in the United S.A.eS.A.d first additional country. Additional amounts may be paid upon approval of additional indications, through net sales payments, and as sales milestones when sales exceed $100 million.
OBI-1 is currently in Phase III clinical studies in individuals with acquired hemophilia A and those with congenital hemophilia A who have developed inhibitorS.A.ainst human FVIII. OBI-1 received orphan drug designation in the United S.A.eS.A.d Europe, and was recently granted fast track designation for acquired hemophilia A by the United S.A.es Food and Drug Administration (FDA).
About Acquired Hemophilia A
Acquired hemophilia A iS.A.very rare (estimated annual incidence of 1.5 cases per million lives) and potentially life-threatening acute bleeding disorder caused by the development of autoantibodies (inhibitors) against coagulation FVIII. In acquired hemophilia A, individuals typically experience soft tissue or post-procedural bleeding, in contrast to bleeding into joints, which is more typical in congenital hemophilia.
About Baxter in Hemophilia
Baxter has more than 60 years experience in hemophilia and has introduced a number of therapeutic firsts for hemophilia patients. Baxter has the broadest portfolio of hemophilia treatments in the industry and iS.A.le to meet individual therapy choices, providing a range of optionS.A. each treatment S.A.e. The company’s work is focused on optimizing hemophilia care and improving the lives of people living with hemophilia A and B worldwide.
About Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops, manufactureS.A.d markets products that save and suS.A.n the lives of people with hemophilia, immune disorders, cancer, infectious diS.A.es, kidney diS.A.e, trauma and other chronic and acute medical conditions. AS.A.global, diversified healthcare company, Baxter applieS.A.unique combination of expertise in medical devices, pharmaceuticalS.A.d biotechnology to create products that advance patient care worldwide.
This release includes forward-looking S.A.ements concerning an agreement made by the company to acquire certain assets from Inspiration BioPharmaceuticals, Inc. and Ipsen Pharma S.A.S., including expectations regarding upfront and other future payments. The S.A.ementS.A.e based on assumptionS.A.out many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking S.A.ements: the ability of the parties to obtain bankruptcy court approval and other required regulatory approvalS.A.d to otherwise satisfy other closing conditions; continued strength in the company's financial position, including cash flows; actions of regulatory bodieS.A.d other governmental authorities; changes in lawS.A.d regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on its website. Baxter does not undertake to update its forward-looking S.A.ements.
Source: Baxter
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!